Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages

Key Points

• Eight analysts give Fate Therapeutics an average recommendation of “Hold” (1 sell, 4 hold, 3 buy) with a 12‑month average price target of $4.10.
• Shares trade around $1.37 with a market cap of about $159.3M and a 52‑week range of $0.91–$1.94; the company reported Q4 EPS of -$0.27 (in line with estimates) and analysts forecast -$1.63 EPS for the year.
• Institutional ownership is very high at 97.54%, with notable recent buying by Comerica, AQR, Jane Street, Geode and Invesco.

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE - Get Free Report) have earned an average recommendation of "Hold" from the eight research firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $4.10.

Separately, Weiss Ratings reissued a "sell (e+)" rating on shares of Fate Therapeutics in a research report on Thursday, January 22nd.

Fate Therapeutics Stock Performance

Fate Therapeutics stock opened at $1.37 on Friday. The stock has a 50-day simple moving average of $1.27 and a 200 day simple moving average of $1.21. The stock has a market capitalization of $159.28 million, a P/E ratio of -1.19 and a beta of 2.23. Fate Therapeutics has a 52 week low of $0.91 and a 52 week high of $1.94.

Fate Therapeutics (NASDAQ:FATE - Get Free Report) last released its quarterly earnings data on Thursday, February 26th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.27). Fate Therapeutics had a negative return on equity of 55.02% and a negative net margin of 2,051.08%.The firm had revenue of $1.37 million for the quarter, compared to analyst estimates of $1.20 million. Research analysts forecast that Fate Therapeutics will post -1.63 earnings per share for the current year.

Institutional Investors Weigh In On Fate Therapeutics

Several hedge funds have recently bought and sold shares of the stock. Comerica Bank grew its position in shares of Fate Therapeutics by 55,698.6% in the first quarter. Comerica Bank now owns 82,024 shares of the biopharmaceutical company's stock valued at $65,000 after purchasing an additional 81,877 shares during the last quarter. AQR Capital Management LLC lifted its holdings in Fate Therapeutics by 296.4% during the 1st quarter. AQR Capital Management LLC now owns 585,025 shares of the biopharmaceutical company's stock worth $462,000 after purchasing an additional 437,423 shares during the last quarter. Jane Street Group LLC boosted its stake in Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 32,911 shares during the period. Geode Capital Management LLC boosted its stake in Fate Therapeutics by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,429,167 shares of the biopharmaceutical company's stock valued at $2,721,000 after purchasing an additional 159,558 shares during the period. Finally, Invesco Ltd. grew its holdings in Fate Therapeutics by 19.6% in the 2nd quarter. Invesco Ltd. now owns 255,372 shares of the biopharmaceutical company's stock valued at $286,000 after buying an additional 41,869 shares in the last quarter. 97.54% of the stock is currently owned by institutional investors and hedge funds.

About Fate Therapeutics

Fate Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of first‐in‐class cellular immunotherapies for cancer and immune disorders. The company leverages its proprietary induced pluripotent stem cell (iPSC) platform to create off‐the‐shelf natural killer (NK) and T‐cell products designed to overcome limitations of donor‐derived approaches. Fate's research aims to deliver therapies with consistent quality, increased potency and scalable manufacturing for broad patient access.

Central to Fate's pipeline are multiple iPSC‐derived cell therapy candidates in active clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.